Compare ICMB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | RNTX |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 38.9M |
| IPO Year | N/A | N/A |
| Metric | ICMB | RNTX |
|---|---|---|
| Price | $2.82 | $1.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 42.3K | ★ 234.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | ★ 18.70% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $17,931,778.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | N/A |
| P/E Ratio | $7.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.46 | $1.04 |
| 52 Week High | $3.47 | $3.50 |
| Indicator | ICMB | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 58.01 |
| Support Level | $2.74 | $1.34 |
| Resistance Level | $2.90 | $1.58 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 21.87 | 87.50 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.